New study reveals rheumatoid arthritis begins long before symptoms, opening door to prevention 

SEATTLE, WASH.—September 24, 2025—Scientists have discovered that rheumatoid arthritis (RA) doesn’t start when the pain begins. It silently starts years earlier. RA is a debilitating autoimmune disease that causes painful joint inflammation and damage. The new research reveals that people at risk for RA experience dramatic immune system changes long before they feel symptoms. During this early phase, their bodies fight an autoimmune battle invisibly.  

Researchers at the Allen Institute, in collaboration with the CU Anschutz, University of California San Diego, and Benaroya Research Institute made the discovery. The study, published in the journal Science Translational Medicine delivers the most detailed look available into how rheumatoid arthritis develops, mapping immune changes in at-risk individuals long before symptoms appear and paving the way for earlier treatment and prevention.  

“Overall, we hope this study raises awareness that rheumatoid arthritis begins much earlier than previously thought and that it enables researchers to make data-driven decisions on strategies to disrupt disease development,” said Mark Gillespie, Ph.D., assistant investigator at the Allen Institute and co-senior author with Kevin Deane (CU Anschutz), M.D./Ph.D.; Adam Savage (Allen Institute), Ph.D.; Troy Torgerson (Allen Institute), M.D./Ph.D.; and Gary S. Firestein (UC San Diego), M.D. During the seven-year study, researchers tracked people carrying ACPA antibodies, which are known biomarkers for individuals at-risk for developing RA, and identified previously unknown factors associated with disease development, including widespread inflammation, immune cell dysfunction, and cellular reprogramming.  

“We expect that going forward the findings from this study will support additional studies to identify ways to better predict who will get RA, identify potential biologic targets for preventing RA as well as identify ways to improve treatments for those with existing RA.,” said Kevin Deane, M.D./Ph.D.  

Key Findings    

• Widespread inflammation: Researchers discovered that systemic inflammation was already present throughout the body in at-risk individuals. This wasn't localized joint inflammation, but rather a body-wide inflammatory state that resembles what's seen in people with active RA.  

• Immune cell dysfunction: Several types of immune cells showed significant abnormalities. 

• B cells, which normally produce protective antibodies, had shifted toward a pro-inflammatory state.   

• T helper cells, particularly a subset resembling Tfh17 cells, were dramatically expanded beyond normal levels. These cells play crucial roles in directing immune responses, including autoantibody (antibodies that attack the body’s own tissue) production and their overactivity helps explain why the immune system begins attacking healthy tissue.  

• Cellular reprogramming: Perhaps most remarkably, the study found that even "naive" T cells—immune cells that haven't encountered threats before—showed epigenetic changes. This means the cells' DNA wasn't mutated, but the way genes were turned on and off had been altered, essentially reprogramming these cells before they even encountered their first threat.  

• Joint-like inflammation in blood: The researchers identified monocytes (a type of white blood cell) in the bloodstream that were producing high levels of inflammatory molecules. Significantly, these blood cells closely resembled the macrophages found in the inflamed joint tissue of RA patients, suggesting the disease process was already preparing to target joints.  

The study reveals new early-warning signs (biomarkers and immune signatures) that could help doctors identify who among at-risk individuals is most likely to develop RA, enabling more targeted monitoring and earlier intervention. If caught early, RA could be stopped before it starts – saving patients years of pain and disability. This research may enable a major shift away from reactive treatments that rely on the appearance of joint damage and towards proactive prevention.  

About the Allen Institute  

The Allen Institute is an independent, 501(c)(3) nonprofit research organization founded by philanthropist and visionary, the late Paul G. Allen. The Allen Institute is dedicated to answering some of the biggest questions in bioscience and accelerating research worldwide. The Institute is a recognized leader in large-scale research with a commitment to an open science model. Its research institutes and programs include the Allen Institute for Brain Science, launched in 2003; the Allen Institute for Cell Science, launched in 2014; the Allen Institute for Immunology, launched in 2018; and the Allen Institute for Neural Dynamics, launched in 2021. In 2016, the Allen Institute expanded its reach with the launch of The Paul G. Allen Frontiers Group, which identifies pioneers with new ideas to expand the boundaries of knowledge and make the world better. For more information, visit alleninstitute.org.  

# # #  

Media Contact  

Liz Dueweke, Sr. Communications and Media Relations  

206-225-0596 | Liz.Dueweke@alleninstitute.org